Sleeve gastrectomy is the most common bariatric procedure in the US today. It removes 70 to 80 percent of the stomach including the ghrelin-producing fundus, achieving 50 to 70 percent type 2 diabetes remission at 1 year and 25 to 40 percent at 10 years. The sleeve trades slightly lower diabetes remission than gastric bypass for a simpler operation, lower nutritional risk, and a clear track record.
Anatomy of Sleeve Gastrectomy
- The greater curvature of the stomach is divided vertically
- 70 to 80% of the stomach is removed, including the fundus
- A long, narrow gastric tube (sleeve) ~100 to 150 mL volume remains
- Pylorus and duodenum are preserved — normal nutrient flow is maintained
- Procedure is irreversible — removed stomach cannot be restored
- Performed laparoscopically (5 small incisions) or robotically
- Operative time: 60 to 90 minutes
Mechanism — How Sleeve Treats Diabetes
- Removal of the fundus drops ghrelin (hunger hormone) by 60 to 80% — major satiety effect
- Accelerated gastric emptying delivers nutrients faster to the small bowel
- GLP-1 secretion rises 2 to 3x baseline (less than RYGB’s 5 to 10x)
- PYY (satiety hormone) increases
- Bile acid changes (smaller magnitude than RYGB)
- Gut microbiome remodels — shift toward butyrate-producing species
- Caloric restriction in early post-op weeks
- Insulin sensitivity improves within weeks; full effect over 6 to 12 months
- Weight loss compounds metabolic improvements
Sleeve vs RYGB Outcomes
| Outcome | Sleeve Gastrectomy | Roux-en-Y Gastric Bypass |
|---|---|---|
| T2D remission at 1 year | 50 to 70% | 60 to 80% |
| T2D remission at 5 years | 30 to 45% | 40 to 55% |
| T2D remission at 10 years | 25 to 40% | 30 to 50% |
| %TBWL at 1 year | 25 to 30% | 30 to 35% |
| %TBWL at 5 years | 20 to 25% | 25 to 30% |
| 30-day mortality | 0.1 to 0.3% | 0.3 to 0.5% |
| Major complications | 3 to 5% | 4 to 7% |
| GERD development/worsening | 15 to 25% | Often improved |
| Dumping syndrome | Rare | 10 to 30% |
| Nutritional deficiency risk | Lower | Higher |
| Operative complexity | Simpler | More complex |
| Reversibility | No (stomach removed) | Technically yes, rarely done |
Time Course of Diabetes Improvement After Sleeve
| Time | Typical Status |
|---|---|
| Days 1 to 7 | Most patients off insulin and sulfonylureas; fasting glucose 90 to 130 mg/dL |
| Weeks 2 to 4 | Metformin often held; postprandial glucose improving |
| Months 1 to 3 | A1C drops 1 to 2 points; weight loss 10 to 18% TBWL |
| Months 6 to 12 | A1C nadir reached; weight loss 25 to 30% TBWL |
| Years 2 to 5 | Some weight regain (5 to 10%); A1C stable in remitters |
| Years 5 to 10 | 25 to 40% maintain remission; relapsers usually need fewer meds than pre-op |
When Sleeve Is Preferred Over Bypass
- Simpler procedure preferred (less operative complexity, shorter hospital stay)
- Inflammatory bowel disease — bypass alters absorption in ways that complicate IBD management
- Need for future endoscopic access to duodenum (e.g., chronic pancreatitis screening, biliary access)
- Heavy NSAID requirement — bypass marginal ulcer risk is high with NSAIDs
- Lower nutritional risk priority — preserved duodenum reduces iron, calcium, B12 issues
- Lower BMI within bariatric range (35 to 45)
- Shorter diabetes duration with good beta-cell function — sleeve sufficient
- Older patients with comorbidities favoring shorter operative time
When Bypass Is Preferred Over Sleeve
- Pre-existing severe GERD or large hiatal hernia
- Longer diabetes duration or higher BMI (over 50) where deeper metabolic effect needed
- Need for highest remission probability
- Patient willing to accept higher complication and nutritional risk for metabolic benefit
- Insulin-dependent T2D
- Revision after failed sleeve or band
GERD After Sleeve — The Signature Concern
- 15 to 25% develop new or worsened GERD
- Mechanisms: high intragastric pressure, disruption of angle of His, hiatal hernia, lower esophageal sphincter laxity
- Symptoms: heartburn, regurgitation, cough, hoarseness, dental erosion
- Management: PPIs, lifestyle (head of bed elevation, no late-evening meals, weight loss progress), avoid trigger foods
- Barrett’s esophagus risk: low but present — endoscopic surveillance for symptomatic patients
- Conversion to RYGB within 5 years for refractory GERD: ~5%
- Pre-op endoscopy and concurrent hiatal hernia repair reduce post-op GERD
Other Sleeve-Specific Complications
- Leak along the staple line: 1 to 2% — managed with stents, drainage, sometimes reoperation
- Bleeding: 1 to 2%
- Stenosis or stricture at the incisura angularis: 1 to 4% — endoscopic dilation usually effective
- Gastric tube twist or kink (rare)
- Portomesenteric venous thrombosis: rare but serious
- VTE: 0.5 to 1%
- Nutritional deficiencies (B12, iron, calcium, vitamin D, thiamine): lower than RYGB but still real
Diet Progression After Sleeve
| Phase | Timing | Examples |
|---|---|---|
| Clear liquids | Days 1 to 3 | Water, broth, sugar-free gelatin, decaf tea |
| Full liquids | Days 4 to 14 | Protein shakes, strained cream soups, sugar-free pudding |
| Pureed | Weeks 2 to 4 | Blended cottage cheese, Greek yogurt, mashed avocado, pureed fish |
| Soft foods | Weeks 4 to 6 | Soft eggs, baked fish, lean ground meat, cooked vegetables |
| Regular textures | Week 6 to 8 onward | Lean proteins, vegetables, modest portions of complex carbs |
Key principles: 60 to 80 grams of protein daily, small frequent meals, no drinking with meals (separate fluids and solids by 30 minutes), chew slowly, stop at satiety. Avoid carbonated drinks, simple sugars, fried foods.
Supplements After Sleeve
- Bariatric multivitamin twice daily (for first 6 to 12 months, then daily for life)
- Calcium citrate 1200 to 1500 mg daily split doses
- Vitamin D 3000 IU daily (titrate to level 30 to 50 ng/mL)
- Vitamin B12 500 to 1000 mcg sublingual daily or 1000 mcg IM monthly
- Iron 18 to 27 mg daily (more if menstruating or anemic)
- Protein supplements during liquid/puree phases
- Labs every 3 months for 1 year, then every 6 to 12 months for life
Long-Term Follow-Up
- 2-week, 1-month, 3-month, 6-month, 1-year visits with bariatric program
- Annually for life: weight, A1C, lipid panel, nutrient panel, GERD assessment
- Bone density every 2 to 5 years
- Endoscopy if persistent reflux or new symptoms
- Mental health support — depression and substance use disorder elevated after bariatric surgery
- Diabetes recurrence: restart pharmacotherapy at lower threshold; GLP-1 RAs first-line
Weight Regain and Diabetes Relapse
- 5 to 10% weight regain typical by year 5
- 20 to 30% have more significant regain (more than 20% of lost weight)
- Diabetes relapse correlates with regain and beta-cell exhaustion
- Add GLP-1 RA (semaglutide, tirzepatide) for regain — increasingly common strategy
- Revision to RYGB or BPD-DS considered in selected refractory cases
- Behavioral support (nutrition, exercise, psychology) remains the foundation
Related Reading
See our foundational bariatric surgery for diabetes overview, the gastric bypass remission deep dive, and bariatric surgery recovery. STAMPEDE 5-year results are at the New England Journal of Medicine.
The Bottom Line
Sleeve gastrectomy is the most common bariatric procedure in the US and a powerful treatment for type 2 diabetes plus obesity — 50 to 70 percent remission at 1 year, 25 to 40 percent at 10 years. The sleeve removes 70 to 80 percent of the stomach including the ghrelin-producing fundus, raising GLP-1 and PYY and accelerating gastric emptying. Compared with gastric bypass, sleeve has slightly lower diabetes remission rates but a simpler operation, lower nutritional risk, and similar safety profile — making it a strong choice for many patients. The big trade-off is GERD: 15 to 25 percent develop or worsen reflux, and about 5 percent need conversion to bypass within 5 years. Pre-op endoscopy, careful surgical technique, lifelong supplementation, and annual follow-up are essential. Discuss with a multidisciplinary bariatric program which procedure fits your anatomy, GERD history, diabetes duration, and goals.
